Gemphire Therapeutics Announces Workforce Reduction
September 24, 2018 17:06 ET
|
Gemphire Therapeutics Inc.
LIVONIA, Mich., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 13, 2018 16:01 ET
|
Gemphire Therapeutics Inc.
LIVONIA, Mich., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric NAFLD
August 10, 2018 06:00 ET
|
Gemphire Therapeutics Inc.
LIVONIA, Mich., Aug. 10, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire Announces Amended and Restated Gemcabene License Agreement with Pfizer Inc.
August 06, 2018 16:01 ET
|
Gemphire Therapeutics Inc.
LIVONIA, Mich., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire Provides Update On Development of Gemcabene
August 06, 2018 16:01 ET
|
Gemphire Therapeutics Inc.
FDA requests the Company provide additional data regarding the partial clinical hold Company continues Phase 2 development of gemcabene for NAFLD/NASH Company amends loan agreement with SVB to...
Gemcabene Meets Primary Endpoint in INDIGO-1 Study of Severe Hypertriglyceridemia (SHTG) Patients
June 28, 2018 16:01 ET
|
Gemphire Therapeutics Inc.
Gemcabene demonstrated statistically significant lowering of triglycerides (TGs) in SHTG Secondary endpoints achieved included statistically significant reductions in serum LDL-C, non-HDL-C, VLDL-C,...
Gemphire Therapeutics Provides the American Liver Foundation an Educational Grant in Support of Disease State Awareness for Pediatric NAFLD
May 18, 2018 09:29 ET
|
Gemphire Therapeutics Inc.
Webinar on Wednesday, May 23, at 8:00am Eastern Time LIVONIA, Mich., May 18, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company...
Gemphire Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 08, 2018 16:01 ET
|
Gemphire Therapeutics Inc.
LIVONIA, Mich., May 08, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire Therapeutics Announces the Appointment of Steven Gullans, Ph.D., as President and Chief Executive Officer
May 03, 2018 16:01 ET
|
Gemphire Therapeutics Inc.
LIVONIA, Mich., May 03, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(C)(4)
April 12, 2018 16:01 ET
|
Gemphire Therapeutics Inc.
LIVONIA, Mich., April 12, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...